Jabari, Duaa
Vedanarayanan, V. V.
Barohn, Richard J.
Dimachkie, Mazen M.
Article History
First Online: 28 June 2018
Compliance With Ethical Standards
:
: Dr. Barohn reports personal fees from NuFactor, Plan 365 Inc., Novartis Pharmaceuticals, Option Care, and PlatformQ Health Education and grants from Eli Lilly and Company, PTC Therapeutics, Cytokinetics, Inc., Neuraltus Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., ALSA, MDA-Myotonic Dystrophy Foundation, The Marigold Foundation, Sarepta Therapeutics, Ionis Pharmaceuticals, TEVA Pharmaceuticals, Biomarin, Sanofi/Genzyme, NIH, FDA/OOPD, and outside the submitted work.Dr. Dimachkie is a consultant or on the speaker’s bureau for Alnylam, Audentes, Biomarin, Catalyst, CSL-Behring, Genzyme, Mallinckrodt, Novartis, NuFactor, Octapharma, Sanofi, Shire and Terumo. Dr. Dimachkie received grants from Alexion, Alnylam, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, CSL-Behring, FDA/OPD, GlaxoSmithKline, Genentech, Grifols, MDA, NIH, Novartis, Genzyme, Octapharma, UCB Biopharma, Viromed and TMA.Drs. Jabari and Vedanarayanan have nothing to disclose.
: This article does not contain any studies with human or animal subjects performed by any of the authors.